Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape
May 20th 2024Medical experts examine the current standards of care and successive lines of treatment for HER2-positive metastatic breast cancer, while also addressing the challenges encountered in managing this complex disease.
Read More
The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients
May 20th 2024Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.
Read More
Practical Considerations for ADC Selection in HR+/HER2- mBC
August 22nd 2023Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.
Read More
HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway
August 8th 2023Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.
Read More
Potential Approaches to Treatment Switching in HR+/HER2- mBC
August 1st 2023Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.
Read More
Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice
August 1st 2023Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.
Read More
The SONIA Trial: Exploring CDK4/6 Inhibitor Efficacy in the First- and Second-Line Settings
July 25th 2023Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.
Read More